Also known as: Diacomit; STP
Stiripentol is an antiepileptic drug indicated as an adjunct to clobazam and valproate for treating Dravet syndrome (severe myoclonic epilepsy in infancy). Mediocon Inc supplies pharmaceutical-grade Stiripentol conforming to IP / BP / EP / USP specifications.
Stiripentol acts by potentiating GABA-A receptor activity and inhibiting cytochrome P450 enzymes, enhancing the efficacy of co-administered antiepileptic drugs. It is an orphan drug for rare paediatric epilepsy.
Key Features
Applications
Why Choose Mediocon
| Parameter | Specification |
|---|---|
| Assay | NLT 98.0% |
| Loss on Drying | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| Residue on Ignition | NMT 0.1% |
| Microbial Limits | Complies with pharmacopoeia |
| Identification | IR, HPLC Compliant |
| Mfg Date | MAR 2025 |
| Exp Date | FEB 2031 |
| Packing | 25 kg HDPE drums / as per requirement |